Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gabapentin enacarbil - Arbor Pharmaceuticals

Drug Profile

Gabapentin enacarbil - Arbor Pharmaceuticals

Alternative Names: 1838262; ASP8825; Gabapentin-XP; GSK 1838262; Horizant; Regnite; Solzira; XP13512

Latest Information Update: 11 Apr 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator XenoPort
  • Developer Arbor Pharmaceuticals; Astellas Pharma; GlaxoSmithKline; National Institute on Alcohol Abuse and Alcoholism; XenoPort
  • Class Acetic acids; Antiepileptic drugs; Carbamates; Cyclohexanecarboxylic acids; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators; GABA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Restless legs syndrome

Highest Development Phases

  • Marketed Postherpetic neuralgia; Restless legs syndrome
  • No development reported Alcoholism
  • Discontinued Diabetic neuropathies; Migraine

Most Recent Events

  • 11 Mar 2019 No development reported - Phase-II for Alcoholism in USA (PO)
  • 28 Feb 2019 No recent reports of development identified for phase-I development in Restless legs syndrome(In adolescents) in USA (PO, Tablet)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top